Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Increased production of a secreted glycoprotein in engineered CHO cells through amplification of a transcription factor.

Mangalampalli VR, Mowry MC, Lipscomb ML, James RI, Johnson AK, Kompala DS.

Cytotechnology. 2002 Jan;38(1-3):23-35. doi: 10.1023/A:1021125208710.

2.

An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody.

Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, Prewett M, Deevi DS, Kearney J, Surguladze D, Jimenez X, Iacolina M, Bassi R, Zhou K, Balderes P, Mangalampalli VR, Loizos N, Ludwig DL, Zhu Z.

Biochem Biophys Res Commun. 2007 Jun 15;357(4):1142-7. Epub 2007 Apr 19.

PMID:
17462601
3.

Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.

Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, Li H, Navarro E, Balderes P, Jimenez X, Koo H, Mangalampalli VR, Ludwig DL, Tonra JR, Hicklin DJ.

Clin Cancer Res. 2006 Nov 1;12(21):6573-84.

4.

Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.

Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, Rolser R, Malikzay A, Persaud A, Corcoran E, Deevi DS, Balderes P, Bassi R, Jimenez X, Joynes CJ, Mangalampalli VR, Steiner P, Tonra JR, Wu Y, Pereira DS, Zhu Z, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Kussie P.

Mol Cancer Ther. 2005 Mar;4(3):369-79.

Supplemental Content

Loading ...
Support Center